Farmas USA

BSDM

6 compras insiders de acciones alrededor de 27000 cada una a 1,1 $ el 2 de mayo.

Soy fan de Wendy :D (Absteneos de abrir los enlaces aquellos a los que no os guste la caspa dura)

http://www.youtube.com/watch?v=ZO8R1kjpoo0
http://www.youtube.com/watch?v=DuoCd7UEkpc

Yo también me arriesgo a meterme cuando hay pánico. Por ejemplo, cuando CAF bajó de forma inexplicable hace unas semanas. Parece que ya recupera y se confirma o parece confirmar que la empresa es la misma de siempre, una de las mejores del continuo.

Pero cuando hay pánico por una empresa farmaceútica que ha hecho dos diluciones y ocultado datos en el pasado, perdonadme, lo que ocurre es que el retail entiende que PUDIERA HABER motivos fundados para entrar en pánico porque NO SE FÍA DE LA EMPRESA a estas alturas.

Y eso sí que no me gusta nada.

Jajaja. Animalico. Ya tardas en hacer ejercicios.

CYTK

Informe trimestral. Yo diría que está bien.

Net loss per share allocable to common stockholders — basic and diluted $ (0.09)

We recorded total revenues of $0.8 million and $1.8 million for the first quarter of 2013 and 2012, respectively.

the Company believes that its existing cash, cash equivalents and investments at
March 31, 2013 will be sufficient to fund its cash requirements for at least the next 12 months

Research and development revenues from related parties for the first quarter of 2013 and 2012 consisted of research and development revenues from our
strategic collaboration with Amgen. Research and development revenues from Amgen were $0.3 million and $1.2 million for the first quarter of 2013 and
2012, respectively, and in both periods consisted of reimbursements of FTE expenses and other research and development expenses. The research activities
under our collaboration with Amgen are anticipated to continue through December 2014.

Research and development, grant and other revenues were $0.5 million and $0.6 million for the first quarter of 2013 and 2012, respectively. Research
and development, grant and other revenues in the first quarter of 2013 included grant revenue from the NINDS of $0.1 million and research and development
revenues from MyoKardia, Inc. of $0.4 million. Research and development, grant and other revenues in the first quarter of 2012 included grant revenue from
the NINDS of $0.3 million and research and development revenue from Global Blood Therapeutics, Inc. of $0.3 million.

We anticipate that revenue for the full year 2013 will be in the range of $1 million to $3 million.

Research and development expenses were $9.8 million and $8.7 million in the first quarter of 2013 and 2012, respectively.

General and administrative expenses were $3.6 million and $3.1 million in the first quarter of 2013 and 2012, respectively

The Company’s financial statements contemplate the conduct of the Company’s operations in the normal course of business. The Company has
incurred an accumulated deficit of $461.5 million since inception and there can be no assurance that the Company will attain profitability. The Company had
a net loss of $12.6 million and net cash used in operations of $12.2 million for the three months ended March 31, 2013. Cash, cash equivalents and
investments decreased to $61.6 million at March 31, 2013 from $74.0 million at December 31, 2012. The Company anticipates that it will continue to have
operating losses and net cash outflows in future periods.

CLSN

Informe trimestral cojonudo y anuncia presentación de los datos del HEAT en una conferencia especializada el 16 de mayo, la World Conference on Interventional Oncology.

http://investor.celsion.com/releaseDetail.cfm?ReleaseID=763472

SNTA

Lo que nos puede pasar es que retiren su presentación del ASCO alegando que les ha dimitido el que tenía que presentar resultados. Eso podría indicar que el estudio ha salido mal, pero, lo que tu dices, en dos meses olvidado. Al final parece que los fundamentales no le importan a nadie.

hijo puta el AF que nos ha tirado el pre de AMRN.
Pero a la gente que le pasa!!?? por que le siguen?